Guisier F, Descourt R, Babey H, Huchot E, et al. Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 >/=50% (GFPC 01-20 Study). Clin Lung Cancer 2022 Sep 17. pii: S1525-7304(22)00203.
PMID: 36210290